View Item 

Show simple item record

Infection prophylaxis patterns following pediatric autologous hematopoietic stem cell transplantation: A survey of Pediatric Transplant and Cell Therapy Consortium centers
dc.contributor.authorFalcon, Corey P.
dc.contributor.authorBroglie, Larisa
dc.contributor.authorPhelan, Rachel
dc.contributor.authorChoi, Sung W.
dc.contributor.authorAuletta, Jeffery J.
dc.contributor.authorChewning, Joseph H.
dc.date.accessioned2020-12-02T14:38:51Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-12-02T14:38:51Z
dc.date.issued2020-12
dc.identifier.citationFalcon, Corey P.; Broglie, Larisa; Phelan, Rachel; Choi, Sung W.; Auletta, Jeffery J.; Chewning, Joseph H. (2020). "Infection prophylaxis patterns following pediatric autologous hematopoietic stem cell transplantation: A survey of Pediatric Transplant and Cell Therapy Consortium centers." Pediatric Transplantation 24(8): n/a-n/a.
dc.identifier.issn1397-3142
dc.identifier.issn1399-3046
dc.identifier.urihttps://hdl.handle.net/2027.42/163606
dc.description.abstractNo standardized guidelines exist for infectious prophylaxis following pediatric auto‐HSCT. We hypothesized significant variation in clinical practice. Thirty‐three Pediatric Transplant and Cell Therapy Consortium centers completed a survey to assess institutional management. The majority utilize viral (91%) and fungal prophylaxis (94%), but duration varies. Bacterial prophylaxis during neutropenia is instituted by 42%. Our study demonstrates marked practice variability in infectious prophylaxis across centers. Additional research is needed to address patterns of infectious complications and to develop meaningful clinical practice guidelines for pediatric auto‐HSCT.
dc.publisherAmerican Society of Clinical Oncology (ASCO)
dc.publisherWiley Periodicals, Inc.
dc.subject.otherPTCTC survey
dc.subject.otherpost auto‐HSCT infection prophylaxis protocol
dc.subject.otherpediatric autologous HSCT
dc.titleInfection prophylaxis patterns following pediatric autologous hematopoietic stem cell transplantation: A survey of Pediatric Transplant and Cell Therapy Consortium centers
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163606/3/petr13821.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163606/2/petr13821_am.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163606/1/petr13821-sup-0001-FigS1.pdfen_US
dc.identifier.doi10.1111/petr.13821
dc.identifier.sourcePediatric Transplantation
dc.identifier.citedreferenceTurtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR. A distinct subset of self‐renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity. 2009; 31 ( 5 ): 834 ‐ 844.
dc.identifier.citedreferenceMatthay KK, Villablanca JG, Seeger RC, et al. Treatment of high‐risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13‐cis‐retinoic acid. Children’s Cancer Group. N Engl J Med. 1999; 341 ( 16 ): 1165 ‐ 1173.
dc.identifier.citedreferencePark JR, Kreissman SG, London WB, et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high‐risk neuroblastoma (HR‐NB): a Children’s Oncology Group (COG) study. In: Proceedings of the American Society of Clinical Oncology (ASCO) Conference. Chicago, IL: American Society of Clinical Oncology (ASCO); 2016.
dc.identifier.citedreferenceSchmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high‐dose chemotherapy with autologous haemopoietic stem‐cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002; 359 ( 9323 ): 2065 ‐ 2071.
dc.identifier.citedreferenceTomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15 ( 10 ): 1143 ‐ 1238.
dc.identifier.citedreferenceKimura S, Akahoshi Y, Nakano H, et al. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta‐analysis of randomized controlled trials. J Infect. 2014; 69 ( 1 ): 13 ‐ 25.
dc.identifier.citedreferenceChoi YB, Yi ES, Kang JM, et al. Infectious complications during tandem high‐dose chemotherapy and autologous stem cell transplantation for children with high‐risk or recurrent solid tumors. PLoS One. 2016; 11 ( 9 ): e0162178.
dc.identifier.citedreferenceZiegler M, Landsburg D, Pegues D, et al. Fluoroquinolone prophylaxis is highly effective for the prevention of central line‐associated bloodstream infections in autologous stem cell transplant patients. Biol Blood Marrow Transplant. 2018; 25 ( 5 ): 1004 ‐ 1010.
dc.identifier.citedreferenceHorton LE, Haste NM, Taplitz RA. Rethinking antimicrobial prophylaxis in the transplant patient in the world of emerging resistant organisms‐where are we today? Curr Hematol Malig Rep. 2018; 13 ( 1 ): 59 ‐ 67.
dc.identifier.citedreferencePorter DL, June CH. T‐cell reconstitution and expansion after hematopoietic stem cell transplantation: ‘T’ it up!. Bone Marrow Transplant. 2005; 35 ( 10 ): 935 ‐ 942.
dc.identifier.citedreferenceAwwad M, North RJ. Cyclophosphamide (Cy)‐facilitated adoptive immunotherapy of a Cy‐resistant tumour. Evidence that Cy permits the expression of adoptive T‐cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology. 1988; 65 ( 1 ): 87 ‐ 92.
dc.identifier.citedreferenceKeever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T‐cell depleted marrow with recipients of conventional marrow grafts. Blood. 1989; 73 ( 5 ): 1340 ‐ 1350.
dc.identifier.citedreferenceSmall TN. Immunologic reconstitution following stem cell transplantation. Curr Opin Hematol. 1996; 3 ( 6 ): 461 ‐ 465.
dc.identifier.citedreferenceRoberts MM, To LB, Gillis D, et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1993; 12 ( 5 ): 469 ‐ 475.
dc.identifier.citedreferenceHenon PR, Liang H, Beck‐Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant. 1992; 9 ( 4 ): 285 ‐ 291.
dc.identifier.citedreferenceRosillo MC, Ortuno F, Moraleda JM, et al. Immune recovery after autologous or rhG‐CSF primed PBSC transplantation. Eur J Haematol. 1996; 56 ( 5 ): 301 ‐ 307.
dc.identifier.citedreferenceOttinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse‐Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood. 1996; 88 ( 7 ): 2775 ‐ 2779.
dc.identifier.citedreferenceMurata K, Tsukahara T, Emori M, et al. Identification of a novel human memory T‐cell population with the characteristics of stem‐like chemo‐resistance. Oncoimmunology. 2016; 5 ( 6 ): e1165376.
dc.identifier.citedreferenceInazawa N, Hori T, Nojima M, et al. Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol. 2017; 89 ( 2 ): 358 ‐ 362.
dc.identifier.citedreferenceMassoud R, Assi R, Fares E, et al. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation. J Clin Virol. 2017; 95: 36 ‐ 41.
dc.identifier.citedreferenceKaya AH, Tekgunduz E, Akpinar S, et al. Is cytomegalovirus surveillance necessary for patients with low reactivation risk in an autologous hematopoietic cell transplantation setting? Transplant Proc. 2017; 49 ( 8 ): 1911 ‐ 1915.
dc.identifier.citedreferenceMengarelli A, Annibali O, Pimpinelli F, et al. Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. J Infect. 2016; 72 ( 2 ): 265 ‐ 268.
dc.identifier.citedreferenceKawamura K, Hayakawa J, Akahoshi Y, et al. Low‐dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol. 2015; 102 ( 2 ): 230 ‐ 237.
dc.identifier.citedreferencePark H, Youk J, Kim HR, et al. Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. Int J Hematol. 2017; 106 ( 6 ): 801 ‐ 810.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
petr13821-sup-0001-FigS1.pdf
Size:
44.80KB
Format:
PDF
View/Open
Name:
petr13821_am.pdf
Size:
217.8KB
Format:
PDF
View/Open
Name:
petr13821.pdf
Size:
389.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.